The Hindu·2 min read·medium
BMS launches dual immunotherapy for metastatic melanoma
T
The Hindu Bureau
✦AI Summary
Bristol Myers Squibb has launched RELOPDUO in India, a dual immunotherapy treatment for metastatic melanoma. The drug combines nivolumab and relatlimab to target two immune checkpoints, offering improved survival rates for patients.
Bristol Myers Squibb (BMS) has announced the launch of RELOPDUO, a fixed-dose combination of nivolumab and relatlimab) in India following approval from the Central Drugs Standard Control Organisation (CDSCO).
healthbusinessscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in